Global Critical Care Therapeutics Market 2017-2021

集中治療用医薬品の世界市場2017-2021

◆タイトル:Global Critical Care Therapeutics Market 2017-2021
◆商品コード:IRTNTR11654
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年1月20日
◆ページ数:101
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥395,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥508,500見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、集中治療用医薬品の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、集中治療用医薬品の世界市場規模及び予測、用途別分析、薬剤種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Critical Care Therapeutics
Critical care or intensive care is the close monitoring and treatment given to individuals with acute, life-threatening illness or injuries such as shock, burns, accidents, complicated surgeries, sepsis, and severe breathing problems. It usually takes place in an ICU or trauma center. Plasma is the fluid portion of the blood, in which all the blood cells are suspended. It makes up about 55% of the total volume of the blood. The other components such as red blood cell (RBC), white blood cell (WBC), and platelets together comprise the remaining 45% of the blood. Plasma is mainly made up of water, which accounts for about 91% of the total volume.

Technavio’s analysts forecast the global critical care therapeutics market to grow at a CAGR of 3.62% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global critical care therapeutics market for 2017-2021. To calculate the market size, the report considers the revenue generated from sales of critical care therapeutics was considered.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Critical Care Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• CSL Behring
• Grifols
• Kedrion Biopharma
• Octapharma
• Shire

[Other prominent vendors]
• Abeona Therapeutics
• ADMA Biologics
• Albumedix
• Armetheon
• Asklepios BioPharmaceutical
• Aspen Pharma
• Baxter
• Bayer HealthCare
• Bio Products Laboratory
• BioDelivery Sciences
• Biogen Idec
• BioMarin
• Biotest Pharmaceuticals
• Bristol-Myers Squibb
• Catalyst Biosciences
• China Biologic Products
• Cosmo Pharmaceuticals
• Kamada
• King Pharmaceuticals
• Medxbio
• Merck
• Mitsubishi Tanabe Pharma
• Novo Nordisk
• Novozymes
• Portola Pharmaceuticals
• ProMetic Life Sciences
• rEVO Biologics
• Rockwell Medical
• Sanquin
• Shanghai RAAS
• Teva Pharmaceutical
• The Medicines Company
• Thermo Fisher Scientific
• Tianjin SinoBiotech & Beijing Bio-Fortune
• Ventria Bioscience

[Market driver]
• Growing preference for marketed products over alternative treatment options.
• For a full, detailed list, view our report

[Market challenge]
• Existence of plasma fractionation supply and demand gap.
• For a full, detailed list, view our report

[Market trend]
• Increased development of recombinant products for critical care use.
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Key market highlights
• The role of plasma therapeutics in critical care industry
• Introduction to plasma therapeutics
• Introduction to anticoagulants

PART 05: Global critical care therapeutics: Market landscape
• Market overview
• Five forces analysis

PART 06: Market segmentation by drug class
• Global albumin market
• Global prothrombin complex concentrates market
• Global antithrombin concentrates market
• Global factor XIII concentrates market
• Global fibrinogen concentrates market

PART 07: Market segmentation by application
• DVT
• Pulmonary embolism (PE)
• Acute coronary syndrome
• Atrial fibrillation
• Hemodialysis
• Coronary angioplasty
• Surgeries

PART 08: Geographical segmentation
• Critical care therapeutics market in Americas
• Critical care therapeutics market in EMEA
• Critical care therapeutics market in APAC

PART 09: Market drivers
• High demand for albumin in China
• Increasing surgical procedures
• Growing preference for marketed products over alternative treatment options
• Impact of drivers

PART 10: Market challenges
• Existence of plasma fractionation supply and demand gap
• Spread of pathogenic contaminants
• High regulations of plasma products

PART 11: Impact of drivers and challenges

PART 12: Market trends
• Increased development of recombinant products for critical care use
• Establishment of plasma fractionation facilities in emerging economies by global players
• Strategic initiatives of vendors fueling the market growth

PART 13: Vendor landscape
• Competitive scenario
• Other prominent vendors

PART 14: Key vendor analysis
• CSL Behring
• Grifols
• Kedrion Biopharma
• Octapharma
• Shire

PART 15: Appendix
• List of abbreviations

PART 16: Explore Technavio0

[List of Exhibits]

Exhibit 01: Composition of blood
Exhibit 02: Composition of plasma
Exhibit 03: Process of procurement and manufacturing of plasma therapeutics
Exhibit 04: Regulatory policies of plasma therapeutics life cycle
Exhibit 05: Process of blood coagulation
Exhibit 06: Mechanism of blood coagulation
Exhibit 07: Market snapshot of global critical care therapeutic market
Exhibit 08: Overview of global critical care therapeutic market 2016-2021
Exhibit 09: Global critical care therapeutic market snapshot: Developed and emerging market 2016-2021
Exhibit 10: Global critical care therapeutics market 2016-2021 ($ millions)
Exhibit 11: Opportunity analysis in global critical care therapeutics market
Exhibit 12: Five forces analysis
Exhibit 13: Market segmentation of global critical care therapeutics by drug class
Exhibit 14: Overview of global albumin market
Exhibit 15: Overview of global prothrombin complex concentrates market
Exhibit 16: Overview of antithrombin concentrates market
Exhibit 17: Overview of global factor XIII concentrates market
Exhibit 18: Overview of global fibrinogen concentrates market
Exhibit 19: Global critical care therapeutics market: Segmentation by geography 2016-2021
Exhibit 20: Global critical care therapeutics market segmentation by region: Market growth life cycle analysis 2016
Exhibit 21: Overview of critical care therapeutics market in Americas
Exhibit 22: Critical care therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 23: Opportunity analysis of critical care therapeutics market in Americas
Exhibit 24: Pest analysis of critical care therapeutics market in Americas
Exhibit 25: Overview of critical care therapeutics market in EMEA
Exhibit 26: Critical care therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 27: Opportunity analysis of critical care therapeutics market in EMEA
Exhibit 28: Pest analysis of critical care therapeutics market in EMEA
Exhibit 29: Overview of critical care therapeutics market in APAC
Exhibit 30: Critical care therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 31: Opportunity analysis of critical care therapeutics market in APAC
Exhibit 32: Pest analysis of critical care therapeutics market in APAC
Exhibit 33: Impact of drivers and challenges on global critical care therapeutics market
Exhibit 34: Impact of drivers
Exhibit 35: Demand and supply gap: Plasma-derived products (million liters/year)
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Impact of trends on global critical care therapeutics market
Exhibit 38: Overview of critical care therapeutics: M&A and licensing partnerships 2005-2012
Exhibit 39: Competitive structure analysis of global critical care therapeutics market 2016
Exhibit 40: Competitive analysis of global critical care therapeutics market
Exhibit 41: Market penetration of various plasma products manufacturers worldwide 2016
Exhibit 42: CSL Behring: Key highlights
Exhibit 43: CSL Behring: Strength assessment
Exhibit 44: CSL Behring: Strategy assessment
Exhibit 45: CSL Behring: Opportunity assessment
Exhibit 46: Grifols: Key highlights
Exhibit 47: Grifols: Strength assessment
Exhibit 48: Grifols: Strategy assessment
Exhibit 49: Grifols: Opportunity assessment
Exhibit 50: Grifols: YoY growth rate and revenue of bioscience segment 2013-2015 ($ billions)
Exhibit 51: Kedrion Biopharma: Key highlights
Exhibit 52: Kedrion Biopharma: Strength assessment
Exhibit 53: Kedrion Biopharma: Strategy assessment
Exhibit 54: Kedrion Biopharma: Opportunity assessment
Exhibit 55: Octapharma: Key highlights
Exhibit 56: Octapharma: Strength assessment
Exhibit 57: Octapharma: Strategy assessment
Exhibit 58: Octapharma: Opportunity assessment
Exhibit 59: Shire: Key highlights
Exhibit 60: Shire: Strength assessment
Exhibit 61: Shire: Strategy assessment
Exhibit 62: Shire: Opportunity assessment



【掲載企業】

CSL Behring, Grifols, Kedrion Biopharma, Octapharma, Shire, Abeona Therapeutics, ADMA Biologics, Albumedix, Armetheon, Asklepios BioPharmaceutical, Aspen Pharma, Baxter, Bayer HealthCare, Bio Products Laboratory, BioDelivery Sciences, Biogen Idec, BioMarin, Biotest Pharmaceuticals, Bristol-Myers Squibb, Catalyst Biosciences, China Biologic Products, Cosmo Pharmaceuticals, Kamada, King Pharmaceuticals, Medxbio, Merck, Mitsubishi Tanabe Pharma, Novo Nordisk, Novozymes, Portola Pharmaceuticals, ProMetic Life Sciences, rEVO Biologics, Rockwell Medical, Sanquin, Shanghai RAAS, Teva Pharmaceutical, The Medicines Company, Thermo Fisher Scientific, Tianjin SinoBiotech & Beijing Bio-Fortune, Ventria Bioscience.

【資料のキーワード】

集中治療、医薬品、アルブミン、濃縮プロトロンビン複合体、アンチトロンビン、フィブリノーゲン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[集中治療用医薬品の世界市場2017-2021] (Global Critical Care Therapeutics Market 2017-2021 / IRTNTR11654)販売に関する免責事項
[集中治療用医薬品の世界市場2017-2021] (Global Critical Care Therapeutics Market 2017-2021 / IRTNTR11654)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆